Received Oct 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Potential TDaP second shot administration under 10 years of age; Potential DTaP administration after 6 years of age; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a male patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. Co-suspect products included DTPa (DTaP vaccine) for prophylaxis. On an unknown date, the patient received the 2nd dose of Boostrix and DTaP vaccine. On an unknown date, an unknown time after receiving Boostrix and not applicable after receiving DTaP vaccine, the patient experienced inappropriate age at vaccine administration (Verbatim: Potential TDaP second shot administration under 10 years of age) and inappropriate age at vaccine administration (Verbatim: Potential DTaP administration after 6 years of age). The outcome of the inappropriate age at vaccine administration and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 15-SEP-2025 A Health Care Provider wanted to know if she could administer Boostrix to an 8-year-old patient that was doing the catch up for the DTaP. The patient only had 1 DTap over 1 year ago and also a TDaP last year. No dates of vaccination nor vaccine's brand names of these last were mentioned, still the adverse event was created for TDaP administration below 10 years of age and the potential administration of the DTaP after the 6 years of age, as well as the potential administration of Boostrix before 10. The Health Care Provider refused to provide any adverse event details (except for the gender). Transfer to second line was attempted, but there were not available agents at the time, so escalation was offered but the Health Care Provider declined it.